Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Iontas
Iontas
Activities:
Ingredients
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
IONTAS identifies SARS-CoV-2 variant neutralising antibodies
The company is now seeking development partners to progress the antibodies
Pharmaceutical
IONTAS celebrates 5 years of antibody discovery
The occasion marks a milestone for the company that provides discovery services and bespoke phage display libraries to the biotechnology and pharmaceutical industries
Pharmaceutical
IONTAS signs collaboration agreement with LG Chem
Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem
Ingredients
Collaboration to identify antibodies for cancer targets
Iontas and IGEM Therapeutics will work together to develop novel immunoglobulin E antibodoes
Ingredients
Iontas to generate antibodies using mammalian display technology
Iontas to generate antibodies with favourable, binding and expression properties using its mammalian display antibody discovery platform
Subscribe now